For citations:

Tolkushin A.G., Rogov V.A., Ivanov D.A., Pogudina N.L. Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(1):19-26. (In Russ.) https://doi.org/10.24411/2588-0519-2019-10061